![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 20, 18084-18090, May 17, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From
Received for publication, March 14, 2001, and in revised form, February 4, 2002
Prostate-specific antigen (PSA) and human
kallikrein 2 are closely related products of the human kallikrein genes
KLK3 and KLK2, respectively. Both PSA and human
kallikrein 2 are produced and secreted in the prostate and have
important applications in the diagnosis of prostate cancer. We report
here the identification of unusual mRNA splice variants of the
KLK2 and KLK3 genes that result from inclusion
of intronic sequences adjacent to the first exon. The novel proteins
encoded by these transcripts, named PSA-linked molecule (PSA-LM) and
hK2-linked molecule (K-LM), share only the signal peptide with the
original protein product of the respective gene. The mature proteins
are entirely different and bear no similarity to the kallikrein family
or to other proteins in the databases. As is the case with PSA, PSA-LM
is expressed in the secretory epithelial cells of the prostate and is
up-regulated in response to androgenic stimulation. A similar pattern
of expression is suggested for K-LM.
Prostate-specific antigen
(PSA)1 is considered the best
cancer biomarker currently available and is widely used for screening, diagnosis, and monitoring of prostate cancer (1, 2). PSA (also named
human kallikrein 3, hK3) is encoded by the KLK3 gene (3), a
member of the human kallikrein gene family (4). These genes are
clustered on chromosome 19q13.3-13.4 and have a highly conserved
structural organization (4, 5). Another member of the kallikrein gene
family, KLK2, displays 80% homology with KLK3
(3, 6) and is located adjacent to it (4). The KLK2 protein
product, human kallikrein 2 (hK2; previously known as human glandular
kallikrein 1, or hGK1), is emerging as an additional prostatic
tumor marker (7).
The kallikrein genes code for a group of serine proteases
involved in post-translational processing of polypeptide precursors to
their bioactive or inactive forms (4). Both PSA and hK2 are regulated
by androgens and are synthesized and secreted by the epithelial cells
of the prostate tubules (8, 9). hK2 is responsible for the activation
of PSA by cleaving its pro-form to the enzymatically active mature form
(10, 11). The mature, catalytically active form of PSA, a glycoprotein
of 237 amino acids, has a chymotrypsin-like activity. PSA acts on
semenogelin I and II, the major gel-forming proteins in seminal plasma,
causing lysis of the seminal clot immediately after ejaculation
(12).
Alternative splicing is a common mechanism for producing functionally
diverse proteins from a single gene (13). In addition to the major
1.6-kb mRNAs, multiple transcripts were found to originate from the
KLK3 and KLK2 genes (14, 15), suggesting the
occurrence of extensive splicing events. Indeed, several alternatively spliced variants have been reported for both genes (15-19). The identity and function of the products encoded by the various
KLK2 and KLK3 mRNA species are not known.
Some of the transcripts formed by alternative splicing events in these
genes are predicted to encode different isoforms of the original PSA
and hK2 proteins.
In this study, we identified alternative transcripts in each of these
genes that arise from unusual splicing events in which sequences from
the first intron remain linked to the first exon in the mature
mRNA, creating new ORFs that encode for novel polypeptides. These
proteins, named PSA-LM and K-LM, share only the signal peptide with PSA
and hK2, respectively. In their mature form, their amino acid sequences
differ completely from the kallikrein family and other proteins in the
databases. Analysis of the pattern of expression of these novel
alternative transcripts and their protein products suggests that, like
PSA and hK2, they are up-regulated by androgens and are expressed
primarily in the secretory cells of the prostate epithelium.
Identification of Alternative Transcripts--
The
LEADSTM platform for clustering and assembly of genomic
sequences, cDNAs and ESTs
(www.labonweb.com/sitehtml/leads_overview_toc.html), was used to
generate the LEADS Transcriptome Database, which includes predicted
transcripts of human genes. The LEADS software models important parts
of the transcription process, including alternative splicing. The LEADS
databases built from GenBankTM versions 106.0 through 120.0 were searched for prostate-specific novel genes and splice variants.
For this purpose, clusters were automatically screened according to the
source tissue of the ESTs and cDNAs. Several clusters were composed
mostly of transcripts from prostate tissues. The resulting clusters
were then subjected to bioinformatic annotation and manually inspected.
This analysis led to the identification of several ESTs that support
the existence of alternative transcripts of the KLK3 gene,
linking exon 1 with the adjacent intronic sequences, and coding for a
putative novel protein (Fig. 1). Among these ESTs are AA506939,
AA524970, AA528287, AI525636, and AI557311.
RNA Isolation--
Total RNA was extracted from cells using the
Tri-Reagent (Molecular Research Center Inc., Cincinnati, OH). Poly(A)
RNA was isolated from total RNA using (dT)25
Dynabeads (Dynal, Oslo, Norway).
RT-PCR--
Reverse transcription (RT) was carried out in a
final volume of 20 µl using 2 µg of total RNA from human tissues or
cell lines and 2.5 units of Superscript II Reverse Transcriptase
(Invitrogen), in the buffer supplied by the manufacturer and
supplemented with 10 pmol of dT15 (Promega, Madison, WI)
and 30 units of RNasin (Promega, Madison, WI). PCR was carried out
using 1 µl of the RT reaction, in the presence of 2 mM
dNTPs, 25 pmol of primers, and 2.5 units of DNA polymerase mix of the
Expand Long Template PCR System (Roche Molecular Biochemicals) in the
reaction buffer supplied by the manufacturer. The following primers
were used: PSA-LM-specific primers were the forward primer A
(5'-CCGGAGAGCTGTGTCACCATGTG-3'), spanning the initiation codon of the
PSA-LM ORF, and the reverse primer E (5'-AAGCAGCTGGGAGCAGGGAGCTG-3'),
at positions 287-309 within the PSA-LM ORF. K-LM-specific
primers were the forward primer H (5'- CTCTCCATCGCCTTGTCTGTGGG-3') at
position 16-38 of this ORF, and the reverse primer L
(5'-GGACAGGGTTGAATGCTC-3') located at nucleotides 19-36 immediately
downstream of the stop codon. PCR products were analyzed on 1.5%
agarose gels, and their identity was verified by DNA sequencing.
RACE Analysis of 5' and 3' Ends--
Rapid amplification of
cDNA ends (RACE) analysis was performed on poly(A) RNA from human
prostate tissue using the Marathon cDNA Amplification Kit
(CLONTECH, Palo Alto, CA). Adaptor-ligated, double-stranded cDNA libraries were prepared essentially as
suggested by the manufacturer. Superscript II Reverse Transcriptase
(Invitrogen) was used for the first strand synthesis. First round PCR
was performed on these libraries using the Expand Long Template PCR
System (Roche Molecular Biochemicals). All PCRs were carried out in the
presence of 1.5 µg of anti-Taq monoclonal antibody
(CLONTECH, Palo Alto, CA). PCR products were
separated on 1.5% agarose gels, purified, and sequenced. A nested PCR
approach was used to isolate 5'- and 3'-RACE products. For 5'-RACE,
first round PCR was carried out with an adaptor-specific primer and the
PSA-LM-specific reverse primer E (described above). Nested PCR was then
performed on these reactions using the reverse primer C
(5'-CCCCAACCATGGCCCCTCTCAC-3') at positions 47-68 in the PSA-LM ORF.
For 3'-RACE, first round PCR was performed with the forward primer A
(described above), and nested PCR with the forward primer B
(5'-GTGAGAGGGGCCATGGTTGGGG-3') derived from positions 47-68 of the
PSA-LM ORF.
Northern Blot Analysis--
Multiple Tissue Northern blot
(MTNTM-Human II), containing poly(A) RNA samples from a
variety of tissues, was purchased from CLONTECH
(Palo Alto, CA). Poly(A) RNA (2 µg) of LNCaP cells was fractionated
by electrophoresis on 1.2% agarose gels containing formaldehyde and
blotted onto Nytran Super Charge membranes (Schleicher & Schuell).
Equal loading was verified by ethidium bromide staining of the gels.
Probes were labeled using the Random Primer DNA Labeling Mix
(Biological Industries, Beit Haemek, Israel) and
[
The following probes were obtained by RT-PCR. PSA probe was a product
of a forward primer (5'-CTTGCTGGGTCGGCACAGCCTG-3') and a reverse primer
(5'-GGTCCCCAGTGCTGGCTCCTGG-3'), both derived from exon 3 of the
KLK3 gene. The PSA-LM probe was a product of the forward
primer D (5'-CCAACCCAGCACCCCAGCCCA-3') at positions 121-141
within the PSA-LM ORF and the reverse primer E (see above). The K-LM
probe was obtained with the forward primer J
(5'-CCCAGCCTCGTCCCTTCAGCC-3') and the reverse primer K
(5'-GGGACCAGTGGCATGGAGAGAGG-3'), at positions 122-142 and 347-369,
respectively, within the K-LM ORF. A 780-bp probe used for the analysis
of hormonal regulation of PSA-LM was derived from intron 1 sequences by
RT-PCR, using the forward primer D and the reverse primer M
(5'-GGTGCTAGGAACCAGGGA- TAAGTG-3').
In Situ Hybridization--
A PSA-LM-specific fragment was
obtained by RT-PCR using the forward primer D (see above) and the
reverse primer F (5'-GGAGGTGGACCAGTGATACGGTCCAAG-3') derived from the
3'-untranslated region of PSA-LM at positions 81-107 downstream of the
stop codon. This fragment was then cloned into the pT-Adv vector
(CLONTECH). Clones in opposite orientations were
used to prepare sense and antisense riboprobes by digoxigenin RNA labeling kit (Roche Molecular Biochemicals). Prostate sections were
prepared as described for immunohistochemistry (see below). In
situ hybridization was performed essentially according to the procedure described by Roche Molecular Biochemicals (20). After deparaffinization and rehydration, sections were digested with proteinase K (10 µg/ml) in 10 mM Tris, pH 8.0, 1 mM EDTA, for 20 min at 37 °C. Hybridization with 0.2-1
µg/ml digoxigenin-labeled riboprobes was carried out in hybridization
buffer (2× SSC, 50% formamide, 0.02% SDS, 10% dextran sulfate, and
0.25 mg/ml salmon sperm DNA) for 4-5 h at 60 °C. Hybridization was
followed by three 20-min washes with 1× SSC and 50% formamide at
55 °C, and two 15-min washes with 1× SSC at room temperature.
Alkaline phosphatase-conjugated anti-digoxigenin antibody was used at
1:500 dilution for 90 min at room temperature, and detection was
obtained by the addition of nitro blue
tetrazolium/5-bromo-4-chloro-3-indolyl phosphate for 15 min at room temperature.
Cell Cultures and Hormonal Stimulation--
The human prostatic
adenocarcinoma cell line LNCaP (ATCC, Manassas, VA) was propagated in
RPMI 1640 containing 10% fetal calf serum. When cells reached 70%
confluency, the culture medium was replaced by phenol red-free RPMI
1640 supplemented with 2% charcoal-stripped fetal calf serum for
24 h, followed by addition of 10 nM methyltrienolone (R1881, PerkinElmer Life Sciences) or testosterone (Fluka) for periods
of 9-48 h.
Expression Constructs and Cell Transfections--
The complete
coding sequences of K-LM or PSA-LM were amplified by RT-PCR and cloned
into the pcDNA4/Myc-His mammalian expression vector (Invitrogen),
enabling the synthesis of proteins fused to the Myc and His epitope
tags at the C terminus. LNCaP cells, at about 70% confluency, were
transfected with these expression constructs using LipofectAMINE
(Invitrogen), according to the manufacturer's instructions. After
48 h, spent media were collected, and cells were washed with
phosphate-buffered saline, harvested, and lysed in 50 mM
Tris, pH 7.5, 150 mM NaCl, 1% Triton X-100, containing a
protease inhibitor mixture (CompleteTM, Roche Molecular
Biochemicals). Proteins from the culture medium were immunoprecipitated
using c-Myc-conjugated agarose beads (9E10 AC, Santa Cruz Biotechnology
Inc., Santa Cruz, CA).
Antibodies--
Peptides corresponding to amino acid residues
33-51 of PSA-LM (NH2-CQAEALSPPTQHPSPDREL-COOH) and
residues 85-104 of K-LM (NH2-PSQIPAPSCFTKEQVPRHLC-COOH) were synthesized. Polyclonal antibodies were raised by immunizing rabbits with the PSA-LM and K-LM peptides conjugated to bovine serum
albumin and keyhole limpet hemocyanin, respectively. The anti-PSA
monoclonal antibody used for immunoblot analysis was purchased from
Santa Cruz Biotechnology, Inc. (A67-B/E3). The anti-PSA monoclonal
antibody used for immunohistochemistry was purchased from
Zymed Laboratories Inc. (San Francisco, CA). A mouse
monoclonal anti-c-Myc antibody (9E10) was purchased from Santa Cruz Biotechnology.
Western Blot Analysis--
Tissue extracts, prepared in RIPA
buffer, and cell lysates were fractionated by SDS-PAGE on 15% gels,
transferred onto polyvinylidene difluoride membranes (Bio-Rad), and
subjected to immunodetection using a commercial anti-Myc antibody or
the immunized sera described above. Peroxidase-conjugated donkey
anti-rabbit or anti-mouse IgGs (Jackson ImmunoResearch Laboratories,
West Grove, PA) were used as secondary antibodies. Proteins were
visualized with the SuperSignal West Pico or West Femto ECL systems (Pierce).
Immunohistochemistry--
Human prostate samples, taken from
patients with benign prostatic hyperplasia (BPH), were fixed in 10%
buffered formalin, and 3-µm sections were prepared and mounted on
OptiPlusTM slides (BioGenex, San Ramon, CA).
Deparaffinization was performed with xylene for 10 min, and the
sections were rehydrated by rinsing three times with 100% ethanol and
once in 95% ethanol. Slides were washed in double distilled
H2O and then incubated with 3% H2O2 for 5 min. Subsequently, the slides were
washed again in double distilled H2O and twice in
OptimaxTM Wash Buffer (BioGenex, San Ramon, CA).
Immunohistochemical staining was performed using
HistostainTM Plus Bulk Kit (Zymed Laboratories
Inc., San Francisco, CA). The anti-PSA-LM and K-LM polyclonal
antibodies, raised in the course of this study, were used at 1:100 and
1:50 dilutions, respectively. Counterstaining with hematoxylin was employed.
Seminal Fluid Analysis--
Seminal plasma, obtained from
ejaculates after removal of spermatozoa by centrifugation, was diluted
in phosphate-buffered saline containing a protease inhibitor mixture.
Proteins were separated by SDS-PAGE on 15% gels, transferred to
polyvinylidene difluoride membranes, followed by immunodetection as
described above.
GenBankTM Accession Numbers--
The nucleotide
sequence for the PSA-LM transcript that contains all of intron 1 has
been deposited in the GenBankTM database under accession
number AF335478. The second PSA-LM-encoding transcript, derived by
alternative splicing within intron 1, has been deposited under
GenBankTM accession number AF335477. The K-LM encoding
transcript was deposited under GenBankTM accession number
AF336106.
Novel Proteins Predicted by Inclusion of Intronic Sequences in the
KLK3 and KLK2 Genes--
We found prostate-derived, alternatively
spliced variants of the PSA-encoding KLK3 gene by searching
the LEADS Human Transcriptome Database (see "Experimental
Procedures"). These variants include all or part of intron 1, thereby
linking the first exon to the adjacent intronic sequences. RT-PCR was
carried out with primers derived from both sides of this sequence in
order to verify the existence of such transcripts in prostate samples.
This sequence was then elongated using the RACE methodology. A new open
reading frame (ORF) of 312 nucleotides was revealed, beginning with the start codon of PSA and ending in a stop codon within the sequences adjacent to exon 1, which are spliced out as intron 1 in the PSA mRNA (Fig. 1). To characterize these
transcripts, RT-PCR was performed with a forward primer from this ORF
and reverse primers derived from each of the downstream PSA exons.
Sequence analysis of the PCR products indicated that the remaining PSA
introns are spliced out and that PSA coding exons 2-5 are located
downstream of the stop codon of this ORF, serving therefore as
3'-untranslated sequences (Fig. 1). In addition, this analysis revealed
the use of an alternative donor splice site within intron 1 (Fig. 1).
The putative novel protein predicted by this new ORF, which we
designated PSA-linked molecule (PSA-LM), is 104 amino acids long and
shares amino acid sequence identity with PSA only in the N-terminal 15 amino acids that encompass the signal peptide of the pre-form protein
(Fig. 2A). Thus, the mature
PSA and PSA-LM proteins are entirely different.
Based on the close similarity between the KLK3 and
KLK2 genes, and the high level of homology between their
non-coding sequences, including introns (3, 6) (80% in intron 1), we
looked for evidence of similarly spliced transcripts in the
KLK2 gene. Analysis of the intronic sequences adjacent to
exon 1 disclosed an ORF of 423 nucleotides, beginning with the start
codon of hK2 within exon 1 and ending in a stop codon within intron 1 of the KLK2 gene. We verified the existence of alternative
transcripts that include intron 1 and contain this ORF by performing
RT-PCR on prostate samples, using a forward primer at the beginning of
this ORF and a reverse primer immediately after the stop codon. In analogy to PSA-LM, the putative 141-amino acid protein specified by
this new ORF, K-LM (hK2-linked molecule), shares with hK2 only the
N-terminal 15 amino acids, which includes the signal peptide (Fig.
2B), and its mature form displays no similarity with hK2.
The PSA-LM and K-LM proteins exhibit 32% identity and 51% similarity
with each other. These novel proteins show no similarity to any other
protein in the databases and contain no known protein signatures.
Interestingly, however, the PSA-LM and K-LM proteins are rich in
proline residues (16 and 17%, respectively) and in serine/threonine
residues (15 and 19%). Proline-rich proteins often serve as adaptor
molecules, bringing together other proteins (reviewed in Ref. 21).
However, it is not clear whether the proline-rich sequences play a role
in the biological function of these novel polypeptides.
Transcription of PSA-LM Is Restricted to Prostatic Epithelium and
Up-regulated by Androgens--
The tissue-specific expression of
PSA-LM was analyzed by RT-PCR, using a primer from exon 1 and a reverse
primer derived from intron 1 within the new ORF. Out of 12 different
tissues and cell lines examined, the expected PCR fragment was detected
only in prostate and in the prostate-derived cell line LNCaP (Fig.
3A and data not shown). RT-PCR
analysis also showed prostate-specific expression of the K-LM-encoding
transcript (data not shown).
The expression pattern of these transcripts was further studied by
Northern blotting (Fig. 3B). A probe derived from exon 3 of
PSA detected a major transcript of about 1.6 kb only in prostate (Fig.
3B, left panel). Additional minor bands of about 1.9, 3, 5, and 6.5 kb were also observed, in agreement with previous reports (14,
15). A probe specific for PSA-LM, derived from its coding sequences
within intron 1, detected RNA transcripts only in prostatic tissue.
These were the same size as the larger bands seen with the PSA probe
(Fig. 3B, middle panel). This is not surprising because the
PSA probe is included in the PSA-LM 3'-UTR and should therefore also
detect the PSA-LM-encoding transcripts. The relative intensity of these
bands in the left panel of Fig. 3B implies that
the PSA-specific transcript of 1.6 kb is considerably more abundant.
Prostate-specific transcripts were also detected with a probe derived
from the K-LM ORF (Fig. 3B, right panel). The exact nature
of the higher bands observed with these probes is not clear. They might
represent precursors of mature mRNAs or complex alternative
splicing patterns, because several spliced products as well as
alternative polyadenylation have been described for both the
KLK2 and KLK3 genes (15-19). The transcript of
about 3 kb might result from inclusion of intron 1, which contains the novel ORF, as described in Fig. 1A. Inclusion of all introns
would result in a transcript of about 5 kb, whereas the addition of a
1.5-kb-long 3'-UTR, as reported by Liu et al. (17), could explain the 6.5-kb transcript.
The androgenic transcriptional activation of the KLK2 and
KLK3 genes has been studied extensively (8, 9, 16, 23, 24).
We analyzed the effects of androgenic stimulation on the expression of
PSA-LM using the androgen-responsive LNCaP cell line. After 24 h
of hormonal depletion, cells were fed on charcoal-striped serum in the
absence or presence of either testosterone or a synthetic androgen
(R1881). Northern blot analysis with a probe derived from exon 3 of PSA
showed a strong induction of the 1.6-kb PSA-encoding transcript after
exposure to 10 nM R1881 (Fig.
4, left panel) or testosterone
(data not shown) for 9 h, conditions previously shown to yield
maximal expression of PSA mRNA (8). Under these conditions, a
2-6-fold up-regulation of the 3-, 5-, and 6.5-kb transcripts was also
detected using a 780-bp probe derived from intron 1 that spans the
PSA-LM ORF without the signal peptide common to PSA (Fig. 4,
right panel). The nature of the other bands observed with
this probe is not clear. Higher levels of PSA and PSA-LM mRNAs were
also observed up to 48 h (data not shown).
Analysis of prostate sections by in situ hybridization
indicated specific expression of the PSA-LM-encoding transcripts in the
secretory epithelial cells of the prostate tubules (Fig.
5). Expression of PSA in the prostate has
also been shown to be restricted to these cells (8, 25). Taken
together, these results suggest that expression of PSA and PSA-LM
undergo similar modes of transcriptional regulation.
PSA-LM and K-LM Protein Expression and Secretion--
Polyclonal
antibodies were generated against synthetic peptides derived from the
amino acid sequences of PSA-LM and K-LM. In order to verify the
specificity of these antibodies, the full coding sequences of PSA-LM
and K-LM were cloned into the mammalian expression vector pcDNA4,
tagged with Myc and His epitopes. LNCaP cells were transfected with
these constructs, and after 48 h the culture medium was collected,
and cells were harvested and lysed. Immunoblot analysis of the
transfected cell lysates, using an anti-Myc antibody or our polyclonal
antibodies, showed expression of PSA-LM and K-LM (Fig.
6, A and B, left
and middle panels). The observed sizes of these recombinant
proteins (13 and 20 kDa, respectively) are similar to those predicted
from their amino acid sequence (11 and 15 kDa), with the addition of
about 3 kDa of the epitope tags. The additional bands observed in Fig.
6B most likely represent cross-reacting proteins, as they
were not detected with other sera raised against K-LM (not shown). The secretion of these proteins to the growth medium of the transfected cell cultures was confirmed by immunoprecipitation using
anti-Myc-coupled beads, followed by immunodetection with the specific
antibodies (Fig. 6, A and B, right panels).
Endogenous PSA-LM and K-LM proteins could not be detected in LNCaP
cells or other prostate-derived cells either prior or following
androgenic stimulation (data not shown), perhaps due to low protein
levels.
Immunohistochemistry analysis of prostate sections using our PSA-LM and
K-LM polyclonal antibodies and a monoclonal antibody against PSA,
showed that the three proteins are detected only in the secreting cells
of the tubule lumen (Fig. 7). The
specific staining observed within the lumen of some of the tubules in
Fig. 7 could reflect the secretion of these proteins. It is important to bear in mind, however, that the cross-reacting bands detected with
the anti-K-LM antibodies in Fig. 6B raise questions about the specificity of these antibodies and the interpretation of the
immunostaining data presented in Fig. 7C.
The presence of a common signal peptide, the secretion of the
recombinant proteins upon transfection to LNCaP cells, and the specific
expression in the prostatic secretory epithelial cells strongly suggest
that, like PSA and hK2 (26), PSA-LM and K-LM are secreted to the
seminal fluid. Immunoblot analysis of samples of semen plasma and
benign prostatic hyperplasia (BPH) identified a major form of the
native K-LM protein, appearing as 27 kDa (Fig. 8). The appearance of this and fainter
bands in these samples, which are bigger than the expected size of this
protein, could be due to post-translational modifications, such as
glycosylation. This assumption gains support from the presence of
several putative glycosylation sites in its amino acid sequence (not
shown). We failed to identify the PSA-LM protein in these samples,
perhaps due to lower expression levels, lower sensitivity of
antibodies, protein instability, or masking by other proteins as in the
case of complexed PSA (27).
The alternative transcripts of the KLK2 and KLK3
genes described here share the same 5'-untranslated sequences and start
codon with the major mRNA species of the respective gene. In
addition, the novel alternative protein products have the same signal
peptide required for secretion of the original proteins encoded by
these genes. Thus, PSA-LM and K-LM are expected to undergo the same mode of hormonal regulation, expression, and secretion as the PSA and
hK2 proteins. This assumption is indeed supported by the data presented
here. Our observations indicate that expression of PSA-LM is restricted
to the glandular epithelium of the prostate and is up-regulated by
androgens, implying that the same control elements regulate the
transcription of the mRNAs that specify the two distinct protein
products of the KLK3 gene. In addition, similar to PSA and
hK2, the K-LM protein appears to be secreted to the seminal fluid.
There are only a few examples of dual utilization of a single promoter
to yield two polypeptides that, in their mature form, differ entirely
in their amino acid sequences. One extensively studied example is
calcitonin and the calcitonin gene-related peptide. In this case, the
two transcripts share the first three exons and have the same
initiation codon. However, tissue-specific alternative RNA processing
associated with differential use of polyadenylation sites, followed by
N-terminal proteolytic cleavage, generate two peptide hormones with
completely different structures and functions (28). Another example is
the leptin receptor and the leptin receptor gene-related protein
(OBR/OB-RGRP): alternative splicing yields two transcripts that share
only the first two 5'-untranslated exons, but the coding exons are
entirely different, resulting in two polypeptides with no sequence
similarity (29).
The current scientific literature on the physiology and pathobiology of
PSA is somewhat controversial, and the physiological role of PSA is
still not clear (2). It has been suggested that the biological
functions of PSA may be influenced by the activity of other
kallikreins, such as hK2, the activating enzyme of the pro-form of PSA
(7, 10, 11). Efforts are underway to supplement PSA diagnostics with
other markers aimed in particular at enhancing the discrimination
between patients with benign disease and those with prostate cancers.
The hK2 protein is now emerging as an additional prostatic tumor marker
that might have clinical applications complementary to those of PSA
(7). Additional studies are required to evaluate the involvement of
PSA-LM and K-LM in the biology of PSA and hK2, as well as in signaling
pathways that lead to the progression of prostate cancer. Such studies
may also clarify their potential clinical value.
We thank N. Almogy and N. Kossoy of the
Department of Pathology, Tel Aviv Sourasky Medical Center, for their
help and professional advice; H. M. Safer, R. Gill-More, and D. Eshel for critical reading of the manuscript; M. Yehezkeli for help
with graphic work; and A. Faingold for assistance with the figures.
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AF335478, AF335477, and AF336106.
§
These authors contributed equally to this work.
Published, JBC Papers in Press, February 7, 2002, DOI 10.1074/jbc.M102285200
The abbreviations used are:
PSA, prostate-specific antigen;
hK2, human kallikrein 2;
KLK2 and
KLK3, human kallikrein genes 2 and 3;
ESTs, expressed
sequences tags;
ORF, open reading frame;
UTR, untranslated region;
RT, reverse transcription;
RACE, rapid amplification of cDNA ends;
BPH, benign prostatic hyperplasia.
Unusual Alternative Splicing within the Human
Kallikrein Genes KLK2 and KLK3 Gives Rise to
Novel Prostate-specific Proteins*
§,
§,
§,
,
,
,
,
,
,

,
,
, and
Compugen Ltd., 72 Pinchas Rosen St.,
Tel Aviv 69512, the
Department of Immunology, Weizmann
Institute of Science, Rehovot 76100, the ¶ Department of
Urology and the ** Department of Pathology, Tel Aviv Sourasky
Medical Center, 6 Weizmann St., Tel Aviv 64239, Israel, and
§§ Compugen Inc., Jamesburg,
New Jersey 08831
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
-32P]dCTP. Hybridization was carried out in the
EZ-Hybridization Solution (Biological Industries, Beit Haemek, Israel)
at 68 °C for 18 h. The membranes were rinsed twice with 2×
SSC, 0.1% SDS at room temperature, followed by two washes with 0.1×
SSC, 0.1% SDS at 50 °C. Autoradiograms were obtaining by exposing
the membranes to x-ray films. Quantification was performed by
densitometric analysis of hybridizing bands from scanned autoradiograms.
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
![]()
View larger version (7K):
[in a new window]
Fig. 1.
Schematic representation of the
splicing events in the KLK3 gene that generate the PSA
mRNA (top) and the alternative transcripts
encoding PSA-LM (bottom). Alternative splicing of
intron 1 is shown in dark blue. One of the PSA-LM
transcripts includes all of intron 1, whereas the other is derived by
alternative splicing within intron 1 (shown in light blue).
Coding exons (orange) and untranslated sequences
(yellow) are boxed, and their sizes, in base
pairs, are indicated. Exons and introns are not drawn to scale. PSA
exons 1-5 are marked. The red and black
arrowheads indicate initiation and stop codons, respectively, of
the PSA and PSA-LM ORFs.

View larger version (28K):
[in a new window]
Fig. 2.
Nucleotide sequence of the PSA-LM
(A) and K-LM (B) ORFs and flanking
sequences. The start and stop codons are marked in bold
letters, and the donor site at the beginning of intron 1 is
underlined. The alternative donor site within intron 1 in
the sequence of PSA-LM is marked in bold letters and
underlined. The corresponding amino acid sequences are shown
below in single letter abbreviations. The signal peptide sequence,
common to PSA or hK2, is double underlined.

View larger version (69K):
[in a new window]
Fig. 3.
Expression of PSA-LM and K-LM.
A, RT-PCR analysis of PSA-LM expression in several tissues,
using a sense primer from exon 1 and an antisense primer derived from
the PSA-LM ORF. The expected 326-bp product is obtained only with
prostate RNA. +/
indicate the presence or absence of reverse
transcriptase in the reaction. Other tissues and cell lines were
checked and found negative, including colon, kidney, ovary,
B-lymphocytes, and HeLa and T24 cells (not shown). B,
Northern blot analysis with probes for PSA (left panel),
PSA-LM (middle panel), and K-LM (right panel).
The Northern blots contain poly(A) RNA from the following human
tissues: lanes 1, spleen; 2, thymus;
3, prostate; 4, testis; 5, ovary;
6, small intestine; 7, colon; and 8,
leukocytes. Size markers (in kb) are indicated. A different multiple
tissue Northern blot (which included prostate, skeletal muscle, uterus,
heart, stomach, and bladder) was also used (not shown). In all cases
the expression is restricted to prostate. The expected 1.6-kb
transcript is the major band detected with the PSA probe. Several
transcripts, ranging in size from 3 to 6.5 kb, are detected with the
PSA-LM and K-LM probes and weakly with the PSA probe.

View larger version (85K):
[in a new window]
Fig. 4.
Hormonal regulation of PSA and PSA-LM
mRNA expression. Northern blots were prepared by
electrophoresis on 1.2% agarose gels of 2 µg of poly(A) RNA from
LNCaP cells incubated with (+) or without (
) 10 nM of the
synthetic androgen R1881. The left and right
panels, respectively, show the hybridization with a PSA probe
derived from exon 3, or a PSA-LM probe derived from intron 1 that spans
the ORF. Size markers (in kb) are indicated. The major transcript of
1.6 kb and the other minor bands detected with the exon 3-specific
probe show a strong up-regulation in the androgen-treated cells. The
higher molecular weight bands detected with the intron 1-specific probe
also show a significant induction following androgenic
stimulation.

View larger version (144K):
[in a new window]
Fig. 5.
Expression of PSA-LM in human prostate
analyzed by in situ hybridization. An antisense
RNA probe was used to detect PSA-LM-specific mRNA; the sense probe
served as a negative control. The hybridization signal is observed only
with the antisense probe and is restricted to prostatic epithelial
cells. Original magnification is ×40.

View larger version (60K):
[in a new window]
Fig. 6.
Detection of Myc-tagged PSA-LM and K-LM
proteins. LNCaP cells were transfected with pcDNA4 constructs
expressing Myc-tagged PSA-LM (A) and K-LM (B)
proteins (lanes 1) or pcDNA4 vector alone (lanes
2). Cell lysates (60 µg) were fractionated by 15% SDS-PAGE and
subjected to immunodetection with a monoclonal anti-Myc antibody
(left panels), followed by analysis with rabbit sera
immunized against PSA-LM (middle panel in A) or
against K-LM (middle panel in B). Secretion of
the recombinant proteins was verified by immunoprecipitation
(IP) of spent media using Myc-conjugated agarose beads,
followed by immunodetection with the respective sera (right
panels). Size markers (in kilodaltons) are indicated. Equal
loading is shown by the intensity of the nonspecific bands.
IB, immunoblot.

View larger version (130K):
[in a new window]
Fig. 7.
Immunohistochemistry of prostate sections,
using anti-PSA (A), PSA-LM (B), and
K-LM (C)-specific antibodies. Preimmune sera for
the antibodies generated in the course of this study were used as
negative control. Marked staining within the epithelial cells
surrounding the prostate tubules is seen with all three
protein-specific antibodies. We counterstained with hematoxylin.
Original magnifications are ×20.

View larger version (53K):
[in a new window]
Fig. 8.
Secretion of K-LM to seminal fluid and
expression in BPH. Proteins from seminal plasma (25 µg,
lanes 1 and 2) and a BPH sample (100 µg,
lane 3) were separated by 15% SDS-PAGE and subjected to
immunoblot analysis with K-LM-specific polyclonal antibodies.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES

To whom correspondence should be addressed: Compugen Ltd., 72 Pinchas Rosen St., Tel Aviv 69512, Israel. E-mail:
galitr@compugen.co.il.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
1.
Diamandis, E. P.
(1998)
Trends Endocrinol. Metab.
9,
310-316[Medline]
[Order article via Infotrieve] 2.
Diamandis, E. P.
(2000)
Clin. Chem.
46,
896-900 3.
Lundwall, A.
(1989)
Biochem. Biophys. Res. Commun.
161,
1151-1159[CrossRef][Medline]
[Order article via Infotrieve] 4.
Diamandis, E. P.,
Yousef, G. M.,
Luo, L.-Y.,
Magklara, A.,
and Obiezu, C. V.
(2000)
Trends Endocrinol. Metab.
11,
54-60[CrossRef][Medline]
[Order article via Infotrieve] 5.
Harvey, T. J.,
Hooper, J. D.,
Myers, S. A.,
Stephenson, S.-A.,
Ashworth, L. K.,
and Clements, J. A.
(2000)
J. Biol. Chem.
275,
37397-37406 6.
Riegman, P. H.,
Vlietstra, R. J.,
van der Korput, J. A.,
Romijn, J. C.,
and Trapman, J.
(1989)
Biochem. Biophys. Res. Commun.
159,
95-102[CrossRef][Medline]
[Order article via Infotrieve] 7.
Rittenhouse, H. G.,
Finlay, J. A.,
Mikolajczyk, S. D.,
and Partin, A. W.
(1998)
Crit. Rev. Clin. Lab. Sci.
35,
275-368[CrossRef][Medline]
[Order article via Infotrieve] 8.
Young, C. Y.,
Montgomery, B. J.,
Andrews, P. E.,
Qiu, S.,
Bilhartz, D. L.,
and Tindall, D. J.
(1991)
Cancer Res.
51,
3748-3752 9.
Young, C. Y.,
Andrews, P. E.,
Montgomery, B. T.,
and Tindall, D. J.
(1992)
Biochemistry
31,
818-824[CrossRef][Medline]
[Order article via Infotrieve] 10.
Kumar, A.,
Mikolajczyk, S. D.,
Goel, A. S.,
Millar, L. S.,
and Saedi, M. S.
(1997)
Cancer Res.
57,
3111-3114 11.
Lovgren, J.,
Rajakoski, K.,
Karp, M.,
Lundwall, A.,
and Lilja, H.
(1997)
Biochem. Biophys. Res. Commun.
238,
549-555[CrossRef][Medline]
[Order article via Infotrieve] 12.
Lilja, H.
(1993)
World J. Urol.
11,
188-191[Medline]
[Order article via Infotrieve] 13.
Black, D. L.
(2000)
Cell
103,
367-370[CrossRef][Medline]
[Order article via Infotrieve] 14.
Henttu, P.,
Lukkarinen, O.,
and Vihko, P.
(1990)
Int. J. Cancer
45,
654-660[Medline]
[Order article via Infotrieve] 15.
Riegman, P. H.,
Klaassen, P.,
van der Karput, J. A.,
Romijn, J. C.,
and Trapman, J.
(1988)
Biochem. Biophys. Res. Commun.
155,
181-188[CrossRef][Medline]
[Order article via Infotrieve] 16.
Riegman, P. H.,
Vlietstra, R. J.,
van der Korput, J. A.,
Romijn, J. C.,
and Trapman, J.
(1991)
Mol. Cell. Endocrinol.
76,
181-190[CrossRef][Medline]
[Order article via Infotrieve] 17.
Liu, X. F.,
Essan, M.,
Vasmatzis, G.,
Lee, B.,
and Pastan, I.
(1999)
Biochem. Biophys. Res. Commun.
264,
833-839[CrossRef][Medline]
[Order article via Infotrieve] 18.
Heuze, H.,
Olayat, S.,
Gutman, N.,
Zani, M.-L.,
and Courty, Y.
(1999)
Cancer Res.
59,
2820-2824 19.
Tanaka, T.,
Isono, T.,
Yoshiki, T.,
Yuasa, T.,
and Okada, Y.
(2000)
Cancer Res.
60,
56-59 20.
Roche Molecular Biochemicals.
(1996)
Non-radioactive in Situ Hybridization Application Manual
, 2nd Ed.
, pp. 34-56, Basel, Switzerland
21.
Kay, B. K.,
Williamson, M. P.,
and Sudol, M.
(2000)
FASEB J.
14,
231-241 22.
Deleted in proof
23.
Wolf, D. A.,
Schulz, P.,
and Fittler, F.
(1992)
Mol. Endocrinol.
6,
753-762[Abstract] 24.
Sun, Z.,
Pan, J.,
and Balk, S. P.
(1997)
Nucleic Acids Res.
25,
3318-3325 25.
Qui, S.,
Young, C. Y. F.,
Bilhartz, D. L.,
Prescott, J. L., He, W. W.,
and Tindall, D. J.
(1990)
J. Urol.
144,
1550-1556[Medline]
[Order article via Infotrieve] 26.
Lovgren, J.,
Valtonen-Andre, C.,
Marsal, K.,
Lilja, H.,
and Lundwall, A.
(1999)
J. Androl.
20,
348-355 27.
Carroll, P. R.
(2001)
Urology
57,
591-593[CrossRef][Medline]
[Order article via Infotrieve] 28.
Lou, H.,
and Gagel, R. F. J.
(1998)
J. Endocrinol.
156,
401-405[Abstract] 29.
Bailleul, B.,
Akerblom, I.,
and Strosberg, A. D.
(1997)
Nucleic Acids Res.
25,
2752-2758
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
H.-S. Lin, H. S. Talwar, A. L. Tarca, A. Ionan, M. Chatterjee, B. Ye, J. Wojciechowski, S. Mohapatra, M. D. Basson, G. H. Yoo, et al. Autoantibody Approach for Serum-Based Detection of Head and Neck Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2396 - 2405. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang and M. Culty Identification and Distribution of a Novel Platelet-Derived Growth Factor Receptor {beta} Variant: Effect of Retinoic Acid and Involvement in Cell Differentiation Endocrinology, May 1, 2007; 148(5): 2233 - 2250. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. K. Lee, Y. S. Choi, Y. A. Park, and S. Jeong Modulation of Oncogenic Transcription and Alternative Splicing by {beta}-Catenin and an RNA Aptamer in Colon Cancer Cells Cancer Res., November 1, 2006; 66(21): 10560 - 10566. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Amir, R. Wang, H. Matzkin, J. W. Simons, and N. J. Mabjeesh MSF-A Interacts with Hypoxia-Inducible Factor-1{alpha} and Augments Hypoxia-Inducible Factor Transcriptional Activation to Affect Tumorigenicity and Angiogenesis Cancer Res., January 15, 2006; 66(2): 856 - 866. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Adamia, T. Reiman, M. Crainie, M. J. Mant, A. R. Belch, and L. M. Pilarski Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma Blood, June 15, 2005; 105(12): 4836 - 4844. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. P. Michael, L. Kurlender, N. Memari, G. M. Yousef, D. Du, L. Grass, C. Stephan, K. Jung, and E. P. Diamandis Intron Retention: A Common Splicing Event within the Human Kallikrein Gene Family Clin. Chem., March 1, 2005; 51(3): 506 - 515. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. W. Avellar, L. Honda, K. G. Hamil, S. Yenugu, G. Grossman, P. Petrusz, F. S. French, and S. H. Hall Differential Expression and Antibacterial Activity of Epididymis Protein 2 Isoforms in the Male Reproductive Tract of Human and Rhesus Monkey (Macaca mulatta) Biol Reprod, November 1, 2004; 71(5): 1453 - 1460. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-H. Chen, R. Luche, B. Wei, and N. K. Tonks Characterization of Two Distinct Dual Specificity Phosphatases Encoded in Alternative Open Reading Frames of a Single Gene Located on Human Chromosome 10q22.2 J. Biol. Chem., October 1, 2004; 279(40): 41404 - 41413. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Borgono, I. P. Michael, and E. P. Diamandis Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer Mol. Cancer Res., May 1, 2004; 2(5): 257 - 280. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||